Display Options:

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Mineralocorticoid receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Depressive Disorder; Adrenal Hyperplasia, Congenital; Melanoma; Ovarian Hyperstimulation Syndrome; Parkinson Disease; Severe Acute Respiratory Syndrome; Shock, Septic; Addison Disease; Adrenogenital Syndrome

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Addison Disease; Eye Diseases; Hemorrhoids

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Acetylcholinesterase inhibitor
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Hypotension, Orthostatic; Heart Failure; Hypotension; Ileus; Parkinson Disease; Severe Acute Respiratory Syndrome; Spinal Muscular Atrophies of Childhood; Myasthenia Gravis

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: MUSCULOSKELETAL; OTHER
THERAPEUTIC INDICATION: Canavan Disease; Esophageal Stenosis; Fanconi Anemia; Frontotemporal Dementia; Gangliosidoses; Gaucher Disease; Glucose Intolerance; Hematologic Diseases; Inflammation; Leber Congenital Amaurosis; Lymphoma, B-Cell; Parkinson Disease; Red-Cell Aplasia, Pure; Respiratory Syncytial Virus Infections; AIDS-Associated Nephropathy; Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Bell Palsy; Blast Crisis; Burkitt Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Castleman Disease; Churg-Strauss Syndrome; Embolism, Cholesterol; Gastrointestinal Stromal Tumors; Glomerulosclerosis, Focal Segmental; Graves Ophthalmopathy; HIV Infections; Hearing Loss; Hearing Loss, Sensorineural; Hemangioma; Hematologic Neoplasms; Hemophilia A; Hepatitis C; Hepatitis, Alcoholic; Hepatitis, Autoimmune; Hypersensitivity; Idiopathic Pulmonary Fibrosis; IgA Vasculitis; Immunoblastic Lymphadenopathy; Immunoglobulin G4-Related Disease; Kidney Neoplasms; Leukemia, Lymphoid; Lichen Planus, Oral; Lung Diseases; Lung Neoplasms; Lymphohistiocytosis, Hemophagocytic; Lymphoma, AIDS-Related; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoproliferative Disorders; Melanoma; Multiple Sclerosis, Relapsing-Remitting; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Nephritis, Interstitial; Neuromyelitis Optica; Opsoclonus-Myoclonus Syndrome; Pemphigoid, Bullous; Pneumonia, Viral; Polycythemia Vera; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Primary Myelofibrosis; Pulmonary Fibrosis; Stiff-Person Syndrome; Takayasu Arteritis; Thrombocythemia, Essential; Thymus Neoplasms; Vestibular Neuronitis; Alzheimer Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Breast Neoplasms; Cardiomyopathies; Central Nervous System Neoplasms; Cystic Fibrosis; Deafness; Giant Cell Arteritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Graft vs Host Disease; Granulomatosis with Polyangiitis; Heart Diseases; Heart Failure; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Hypereosinophilic Syndrome; Kidney Diseases; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia-Lymphoma, Adult T-Cell; Lupus Nephritis; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Microscopic Polyangiitis; Multiple Myeloma; Muscular Dystrophy, Duchenne; Myasthenia Gravis; Nasal Polyps; Neuroblastoma; Pain; Polymyalgia Rheumatica; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pulmonary Disease, Chronic Obstructive; Purpura, Thrombotic Thrombocytopenic; Renal Insufficiency, Chronic; Retroperitoneal Fibrosis; Rhinitis, Allergic, Perennial; Sarcoidosis, Pulmonary; Sarcoma; Sciatica; Severe Acute Respiratory Syndrome; Sinusitis; Tuberculosis; Urticaria; Uveitis; Uveitis, Intermediate; Vasculitis; Waldenstrom Macroglobulinemia; Addison Disease; Adrenal Hyperplasia, Congenital; Anemia, Aplastic; Anemia, Hemolytic; Arthritis; Arthritis, Gouty; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Berylliosis; Bursitis; Chorioretinitis; Choroiditis; Colitis, Ulcerative; Conjunctivitis, Allergic; Crohn Disease; Dermatitis Herpetiformis; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Exfoliative; Dermatitis, Seborrheic; Dermatomyositis; Erythema Multiforme; Herpes Zoster Ophthalmicus; Hypercalcemia; Iridocyclitis; Iritis; Keratitis; Leukemia; Lupus Erythematosus, Systemic; Lymphoma; Multiple Sclerosis; Mycosis Fungoides; Myocarditis; Nephrotic Syndrome; Ophthalmia, Sympathetic; Optic Neuritis; Osteoarthritis; Pemphigus; Pneumonia; Polymyositis; Psoriasis; Pulmonary Eosinophilia; Purpura, Thrombocytopenic, Idiopathic; Rhinitis, Allergic, Seasonal; Sarcoidosis; Serum Sickness; Spondylitis, Ankylosing; Stevens-Johnson Syndrome; Synovitis; Tennis Elbow; Tenosynovitis; Thrombocytopenia; Thyroiditis, Subacute; Trichinellosis; Tuberculosis, Meningeal; Tuberculosis, Pulmonary; Uveitis, Posterior

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dihydrofolate reductase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Adenocarcinoma; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Colitis, Ulcerative; Cystic Fibrosis; Glioma; Hepatitis C; Hepatitis C, Chronic; Hidradenitis Suppurativa; Insulin Resistance; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphangioleiomyomatosis; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Osteosarcoma; Ovarian Neoplasms; Retinitis Pigmentosa; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Crohn Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glioblastoma; HIV Infections; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lichen Planus; Mastocytosis; Multiple Sclerosis, Chronic Progressive; Neoplasms; Osteoarthritis, Knee; Pancreatic Neoplasms; Porphyria Cutanea Tarda; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Small Cell Lung Carcinoma; Zellweger Syndrome; Abortion, Habitual; Antiphospholipid Syndrome; Arthritis, Rheumatoid; Coronavirus Infections; Giant Cell Arteritis; Graft vs Host Disease; Infections; Influenza, Human; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Osteoarthritis; Pneumonia; Pneumonia, Pneumocystis; Pneumonia, Viral; Pre-Eclampsia; Pregnancy; Respiratory Distress Syndrome; Respiratory Insufficiency; Sarcoidosis, Pulmonary; Severe Acute Respiratory Syndrome; Sjogren's Syndrome; Thrombocytopenia; Malaria

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Parkinson Disease

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus; Fibromyalgia; HIV Infections; Hypotension, Orthostatic; Muscular Atrophy, Spinal

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Burkitt Lymphoma; Leukemia; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Shock, Septic; Asthma; Eye Diseases; Hemorrhoids

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Anxiety; Anxiety Disorders

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: INJECTION; INTRATHECAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Pain; Anesthesia

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Ferriprotoporphyrin IX inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Rheumatic Diseases; Antiphospholipid Syndrome; Cholangiocarcinoma; Lung Diseases, Interstitial; Melanoma; Nephritis, Hereditary; Pancreatic Neoplasms; Coronavirus Infections; Lung Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Severe Acute Respiratory Syndrome; Arthritis, Rheumatoid; Malaria

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Pregnancy; Cataract; Pain

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL; TRANSDERMAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Alcoholism; Fatigue; Hypotension, Orthostatic; Neoplasms; Opioid-Related Disorders; Postoperative Complications; Amphetamine-Related Disorders; Brain Injuries; Chronic Pain; Cocaine-Related Disorders; Feeding and Eating Disorders; Parkinson Disease; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stress Disorders, Post-Traumatic; Substance-Related Disorders; Alzheimer Disease; Anemia, Sickle Cell; Anxiety; Asthenia; Bipolar Disorder; Brain Neoplasms; Delirium; Dementia; Depressive Disorder; Depressive Disorder, Major; Hematologic Neoplasms; Multiple Sclerosis; Tobacco Use Disorder; Attention Deficit Disorder with Hyperactivity; Narcolepsy

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Depressive Disorder

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Digestive System Diseases

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thyroid hormone receptor agonist
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Head and Neck Neoplasms; Multiple Sclerosis; Prostatic Neoplasms, Castration-Resistant; Heart Defects, Congenital; Hernias, Diaphragmatic, Congenital; Hypothyroidism; Myxedema; Thyroid Neoplasms

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Glucocorticoid receptor agonist
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Eye Diseases; Hemorrhoids; Nasal Obstruction

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium channel alpha subunit blocker
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor beta agonist
ROUTE OF ADMINISTRATION: INHALATION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Adrenergic receptor beta agonist
ROUTE OF ADMINISTRATION: INHALATION; INJECTION; RECTAL; SUBLINGUAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Heart Failure

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Synaptic vesicular amine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Hypertension

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypotension, Orthostatic; Lipoma; Orthostatic Intolerance; Atrial Fibrillation; Kidney Calculi; Cardiovascular Diseases; Lung Diseases, Obstructive

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Thyroid hormone receptor agonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Atrial Fibrillation; Heart Failure; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Breast Neoplasms; Euthyroid Sick Syndromes; Hypothyroidism; Shock, Septic; Bipolar Disorder; Depressive Disorder

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Acetylcholinesterase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Androgen Receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Breast Neoplasms; Hypogonadism; Neoplasms; Orchitis

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: D2-like dopamine receptor antagonist
ROUTE OF ADMINISTRATION: INJECTION; ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Dementia; Depressive Disorder; Schizophrenia; Anxiety

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Muscarinic acetylcholine receptor M1 antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Psychotic Disorders

MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Aging; Autistic Disorder; Alcoholism; Depressive Disorder, Major; Macular Degeneration; Tobacco Use Disorder; Hypertension